Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 11/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 5/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.90 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.90 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.90 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL3061897 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL3477364 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL29316 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL30885818 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL940320 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL1559600 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8512218 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8512204 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2030143 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8090431 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12739 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| US-12589070-B2 | Low-dosage orodispersible opioid tablet and method for preparing same | ETHYPHARM (FR) | 2026-03-31 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | claimed |
| US-20250228846-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2025-07-17 | — | — | US | claimed |
| US-12337065-B2 | Compositions for treating viral infections and methods for same | ACCESS TO ADVANCED HEALTH INSTITUTE (US) | 2025-06-24 | — | — | US | claimed |
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | claimed |
| CN-119894893-A | Sulfone substituted pyrido [3,4-D ] pyrimidine derivatives for the treatment of cancer | 拜耳公司 | 2025-04-25 | — | — | CN | claimed |
| EP-0377518-A2 | Sustained release pharmaceutical composition | F.H. FAULDING & CO. LIMITED (AU) | 1990-07-11 | — | — | EP | claimed |
| US-4915685-A | Methods and apparatus for iontophoresis application of medicaments at a controlled ph through ion exchange | IOMED, INC. | 1990-04-10 | — | — | US | claimed |
| EP-0361680-A2 | Morphine-containing composition | RHONE POULENC RORER LIMITED (GB) | 1990-04-04 | — | — | EP | claimed |
| US-4888354-A | INCREASED ABSORPTION RATES | THERATECH, INC. (US) | 1989-12-19 | — | — | US | claimed |
| EP-0321870-A1 | Skin penetration enhancement using free base and acid addition salt combinations of active agents | THERATECH, INC. (US) | 1989-06-28 | — | — | EP | claimed |
| US-4834965-A | Controlled release pharmaceutical composition | EUROCELTIQUE, S.A. (LU) | 1989-05-30 | — | — | US | claimed |
| EP-0299615-A2 | Methods and apparatus for iontophoresis application of medicaments at a controlled pH through ion exchange | University of Utah Research Foundation (US) | 1989-01-18 | — | — | EP | claimed |
| EP-0214735-A1 | Controlled release pharmaceutical composition | Euroceltique S.A. (LU) | 1987-03-18 | — | — | EP | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |
| US-4083982-A | 3-(PARA-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3-PHENYL-PROPYLAMINE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1978-04-11 | — | — | US | claimed |